CAR-T and engineered T cell therapies

Clinical MedicineUpdated Oct 5, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

249 papers

Active filtersClassification:Core

Showing 169-180 of total 249 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2026PubMedDirectly related

Programmable engineered bacteria manipulate metabolism and remodel the TME in situ for enhancing adoptive cell therapy.

Chen J; Liu T; Liu X; Zhang H; Wang C; Meng Y; Wu M; Nomura S; Zhang Z; Yin S; Zhang C; Dong A

2026PubMedDirectly related

Next-generation LMP2A-targeting TCR-recombinant T cells with inducible IL-18 expression to treat EBV-associated malignancies.

Bonifacius A; Mausberg P; Floegel F; Dragon AC; Tischer-Zimmermann S; Stoll S; Rahmati P; Spieler P; Lammoglia Cobo MF; Halenius A; Abken H; Blasczyk R; Nerreter T; Hudecek M; Schambach A; Hansmann L; Maecker-Kolhoff B; Eiz-Vesper B

Jan 1, 2026Molecular therapy. Oncology

2026PubMedDirectly related

Modular delivery of co-stimulatory signals through a PD-1-based immunoswitch receptor improves the functionality of Hepatitis B Virus-specific engineered T cells.

Olguín-Contreras LF; Heep J; Schiller L; Loffredo-Verde E; Festag MM; Metzger K; Färber S; Gültan M; Tulessin M; Wilde S; Wisskirchen K; Noessner E; Protzer U

Jan 1, 2026Frontiers in immunology

2026PubMedDirectly related

Global trends in CAR-T cell therapy for multiple myeloma: A bibliometric analysis, 2013-2025.

Zhang T; Wang S; Li X; Li X; Wu Y

Jan 1, 2026Human vaccines & immunotherapeutics

2026PubMedDirectly related

The promising role of engineered T lymphocytes in immunotherapy for high-grade serous ovarian carcinoma: a review of mechanisms, clinical landscape, and future strategies.

Faradina D; Rusda M; Siregar MFG; Adella CA; Putra A; Prananda AT; Suardi D; Marpaung J; Khosasi F

Jan 1, 2026Journal of the Egyptian National Cancer Institute

2026PubMedDirectly related

From exhaustion to functional cure: frontiers in reversing HBV-specific T-cell immunity.

Liang L; Xie X; He S; Zhou L; Yue Y

Jan 1, 2026Frontiers in immunology

2026PubMedDirectly related

In Situ Generation of Claudin18.2-Specific CAR-T Cells via Lipid Nanoparticle-Mediated mRNA Delivery.

Li H; Li J; Wang Y; Chen L

Jan 1, 2026Journal of visualized experiments : JoVE

2026PubMedDirectly related

Harnessing immunity against breast cancer: from checkpoints to cell therapies.

Mussa A; Hamid M; Talib M; Ismail NH; Lambuk F; Bishir AD; Memon MA; Lukman Y; Suliman R; Yagoub A; Hajisa K; Mokhtar NF; Marincola FM; Mohamud R; Hassan R; Al-Hatamleh MAI

Jan 1, 2026Journal of translational medicine

2026PubMedDirectly related

A phase 1 feasibility trial of BE-CAR33, an "off-the-shelf" base-edited CAR33 T cell therapy for acute myeloid leukemia.

Georgiadis C; Chiesa R; Rashed H; Hughes BK; Preece R; Gough O; Pinner D; Adams S; Thomas R; Etuk A; Mishra A; Zhan H; Braybrook T; Gilmour K; Potter V; Bartram J; Ancliff P; Sauer M; Qasim W; Base Edited-CAR T cell group; Base-Edited CAR T Group

Jan 1, 2026Science translational medicine

2026PubMedDirectly related

Brain barriers at the crossroads of glioma immune surveillance and immunotherapy response.

Engelhardt B; Platten M

Jan 1, 2026Nature reviews. Cancer

2026PubMedDirectly related

Targeting T-cell exhaustion and tumour immune evasion: a review of emerging strategies.

Saltis L; Mun LJ

Jan 1, 2026Pathology, research and practice

2026PubMedDirectly related

Microfluidic T-Chip enables one-step clinical-scale T-cell purification from blood products for CAR T-cell manufacturing.

Rana M; Nigrovic SE; Payan-Medina A; Saha S; Putaturo VR; Cunneely QE; Bell R; Antmen E; Maus MV; Toner M; Elsallab M; Mishra A

Jan 1, 2026bioRxiv : the preprint server for biology